LATA Trial: HIV Injections Beat Daily Pills
Analysis based on 6 articles · First reported Sep 20, 2026 · Last updated Sep 21, 2026
The trial results are positive for makers of long-acting injectable HIV treatments, particularly Johnson & Johnson and ViiV Healthcare, as they support wider adoption and potential expanded labeling in low- and middle-income markets. However, near-term revenue impact is limited by access barriers such as pricing, patents, and cold-chain requirements, so the effect on pharmaceutical equities is likely modest and sentiment-driven.
A clinical trial led by University College London found that long-acting HIV injections given every eight weeks kept the virus suppressed more effectively than daily antiretroviral tablets among adolescents. The LATA (Long-Acting Treatment in Adolescents) trial involved 476 adolescents aged 12 to 19 across five clinics in Kenya, South Africa, Uganda and Zimbabwe. Participants were randomly assigned either standard daily tablet treatment or injections containing the long-acting HIV medicines cabotegravir and rilpivirine. Findings published in The Lancet showed that only two adolescents, or 1 per cent, receiving the injectable treatment experienced confirmed viral rebound after 96 weeks, compared with 15, or 6 per cent, among those taking daily tablets. Nearly all participants in the injectable group, 94 per cent, said receiving treatment every eight weeks was much easier than taking medicines every day. Researchers, including chief investigator Professor Sarah Pett, called for wider access to the treatment in low- and middle-income settings, noting that nine out of 10 adolescents with HIV live in Africa yet currently cannot access the treatment. The trial was funded by the European Union through EDCTP-2 and Johnson & Johnson Innovative Medicines, which provided injectable rilpivirine, while ViiV Healthcare provided injectable cabotegravir. UCL was the study sponsor. Researchers from Kenya, South Africa, Uganda and Zimbabwe contributed to the trial, with additional involvement from the London School of Hygiene and Tropical Medicine, Radboud University Medical Center and the University of York. The World Health Organization currently recommends long-acting injectables as an alternative option for adults and adolescents who have successfully suppressed HIV and do not have active hepatitis B. Expanding access faces challenges including higher cost, patents, refrigeration requirements for rilpivirine, and the need for trained nursing staff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard